CervoMed Inc. (CRVO) - Dilution Analysis

10-Q filing | 9.3M shares outstanding

10-Q filing | 8.7M shares outstanding

10-K filing | 8.1M shares outstanding

10-Q filing | 8.7M shares outstanding

POS AM filing: This prospectus relates to the resale of up to 4,728,916 shares of common stock by selling stockholders.

S-3 filing: CervoMed Inc. may offer and sell shares of its common stock; shares of its preferred stock; debt securities, which may be issued in one or more series and which may be senior debt securities or subordinated debt securities; warrants to purchase shares of its common stock, shares of its preferred stock or its debt securities; units that include any of the foregoing securities; and rights to purchase shares of its common stock, shares of its preferred stock, its debt securities or units with an aggregate offering price of up to $250,000,000.

10-Q filing | 8.7M shares outstanding

S-1/A filing: This is an S-1/A filing for CervoMed Inc. related to the registration of shares of Common Stock held by selling stockholders and shares issuable upon exercise of warrants. Also, it summarizes details of a recent private placement.

10-Q filing | 8.3M shares outstanding

S-1 filing: This S-1 filing registers the resale of common stock and warrant shares acquired through a private placement, to be sold by the selling stockholders listed in the filing.

10-K filing | 6.2M shares outstanding

8-K filing: CervoMed Inc. amended a pre-funded warrant with The Joshua S. Boger 2021 Trust DTD 12/09/2021 to remove beneficial ownership restrictions, followed by the Trust's full exercise of the warrant for 495,959 shares of common stock, resulting in 6,170,479 shares outstanding as of February 27, 2024.

10-Q filing | 5.7M shares outstanding

8-K filing: Stock split 1-for-1.5 | Outstanding: 2,040,066 → 1,360,044

10-Q filing | 2.0M shares outstanding

10-Q filing | 2.0M shares outstanding

10-K filing | 2.0M shares outstanding

10-Q filing | 2.0M shares outstanding

10-Q filing | 2.0M shares outstanding

10-Q filing | 2.0M shares outstanding

8-K filing | Stock split 1-for-50 | Outstanding: 101,914,280 → 2,038,285 | Transactions: Conversion 10000 Preferred stock

8-K filing: Diffusion Pharmaceuticals Inc. entered into subscription agreements to issue Series C Convertible Preferred Stock, intends to call a new special meeting for a reverse stock split at a ratio of not less than one-for-two and not greater than one-for-50, and approved an amendment to its bylaws regarding quorum requirements. ($0.01M proceeds)

10-K filing | 101.9M shares outstanding

10-Q filing | 101.9M shares outstanding

10-Q filing | 101.9M shares outstanding

10-Q filing | 101.9M shares outstanding

10-K filing | 101.9M shares outstanding

8-K filing: Diffusion Pharmaceuticals Inc. completed a public offering of 29,268,294 shares of common stock at $1.025 per share, and H.C. Wainwright & Co. exercised their option to purchase an additional 4,390,244 shares, resulting in aggregate net proceeds of approximately $31.7 million.

10-Q filing | 64.0M shares outstanding

S-3 filing: Diffusion Pharmaceuticals Inc. files an S-3 registration statement to offer and sell common stock, preferred stock, debt securities, warrants, units, and rights to purchase common stock, preferred stock, debt securities, or units, with an aggregate initial offering price of up to $75,000,000.

10-Q filing | 64.0M shares outstanding

S-1/A filing: This prospectus relates to the resale of up to 5,821,429 shares of our common stock, issuable upon exercise of certain outstanding common stock purchase warrants.

S-1 filing: This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption "Selling Stockholders," of up to 5,821,429 shares of our common stock, par value $0.001 per share, issuable upon exercise of certain outstanding common stock purchase warrants.

8-K filing: Diffusion Pharmaceuticals Inc. completed an offering of 11,428,572 shares of common stock at a price of $1.05 per share, resulting in net proceeds of approximately $10.6 million. ($12.0M proceeds)

10-Q filing | 46.0M shares outstanding

8-K filing: Diffusion Pharmaceuticals Inc. closed an offering on May 8, 2020, involving the exercise of warrants and issuance of new warrants, resulting in gross proceeds of approximately $2.375 million and the issuance of 5,000,000 shares of common stock. ($2.38M proceeds)

8-K filing: Diffusion Pharmaceuticals Inc. entered into a warrant exercise agreement with an existing accredited investor to exercise warrants to purchase up to 5,000,000 shares of the Company's common stock at $0.35 per share, with gross proceeds expected to be approximately $2.38 million. The exercising holder will receive new unregistered warrants to purchase up to 5,000,000 shares of common stock at an exercise price of $0.5263 per share. ($2.38M proceeds)

10-K filing | 34.6M shares outstanding